default author photo

Vincent Ribrag

Gustave Roussy - Drug Development Department (DITEP)

Villejuif

France

SCHOLARLY PAPERS

6

DOWNLOADS

574

TOTAL CITATIONS

0

Scholarly Papers (6)

1.

Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet "Recommendations Carried Out within the Framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 10108571. ERN-EuroBloodNet is Partly Co-Funded by the European Union within the Framework of the Fourth EU Health Programme"

Number of pages: 27 Posted: 19 Jun 2024
Gustave Roussy - Drug Development Department (DITEP), Université Libre de Bruxelles (ULB) - Department of Haematology, Maria Sklodowska-Curie National Research Institute of Oncology, Onkologikum Frankfurt am Museumsufer, Aarhus University - Aarhus University Hospital, Canary Islands Health Research Institute Foundation (FIISC), Canary Islands Health Research Institute Foundation (FIISC), Assistance Publique-Hôpitaux de Paris - Hôpital Saint-Louis, University of Pavia - Department of Molecular Medicine, Lymphoma Coalition, Autonomous University of Barcelona - Institut d’Investigació contra la Leucemia Josep Carreras (IJC), CHU Montpellier, Université de Versailles Saint-Quentin, Universitaria di Bologna - Azienda Ospedaliero, Maria Sklodowska-Curie National Research Institute of Oncology and University of Amsterdam - University Medical Center
Downloads 261 (319,183)

Abstract:

Loading...

Burkitt lymphoma, guidelines, tumour lysis syndrome

2.

Infectious Complications in Patients Treated with T-Cell Engager for Solid Tumours or Haematological Malignancies, a Descriptive Study from the REISAMIC Registry

Number of pages: 33 Posted: 12 Nov 2024
University of Paris-Saclay - Department of Hematology, Gustave Roussy, Gustave Roussy, Gustave Roussy, University of Paris-Saclay - Institut Pasteur, Gustave Roussy - Hematology Department, Gustave Roussy - Hematology Department, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Comité de Pathologies Thoraciques, Université Paris Saclay - Department of Children and Adolescents Oncology, Department of Pediatric and Adolescent Oncology, Institut Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Aix Marseille Université, Gustave Roussy, University of Paris-Saclay, Gustave Roussy - Drug Development Department (DITEP) and Gustave Roussy - Drug Development Department (DITEP)
Downloads 115 (621,896)

Abstract:

Loading...

T-cell engager, infections, haematological malignancy, solid tumour

3.

Results of the EpiRCHOP Phase II Study on the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Patients Newly Diagnosed with Diffuse Large B Cell Lymphoma: A LYSA Study

Number of pages: 32 Posted: 30 Oct 2024
Université de Versailles Saint-Quentin, Université Paris Cité, Centre Henri Becquerel, Normandie University, IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, CHU Rennes, Centre Hospitalier de Chambéry, Centre Henri Becquerel, CHU Montpellier, University of Nantes - CHU Nantes, University of Paris - Department of Hemato-Oncology, Assistance Publique-Hôpitaux de Paris, CHU de Poitiers, Central University Hospital of Liege, Centre Hospitalier Universitaire UCL Namur, Centre Henri Becquerel, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Lyon-Sud - Hospices Civils de Lyon, Centre Henri Becquerel, University of Lille and Gustave Roussy - Drug Development Department (DITEP)
Downloads 78 (823,616)

Abstract:

Loading...

diffuse large B cell lymphoma, EZH2, phase II

4.

Sequence Analyses of Relapsed or Refractory Diffuse Large B-Cell Lymphomas Unravels Three Genetic Subgroups of Patients and GNA3 Mutant as Poor Prognosis Biomarker, Results of LNH-EP1 Study

Number of pages: 35 Posted: 14 Mar 2022
Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Translational Research Hematological Laboratory, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Hematology Department, Gustave Roussy - Hematology Department, Gustave Roussy - Hematology Department, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Hematology Department, Gustave Roussy - Hematology Department, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Medical Imaging Department, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Medical Imaging Department, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Hematology Department, Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Hematology Department, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), INSERM U1170, Université Paris-Saclay, Gustave Roussy, Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Translational Research Hematological Laboratory and Gustave Roussy - Drug Development Department (DITEP)
Downloads 63 (933,592)

Abstract:

Loading...

Lymphoma large B-cell diffuse, Molecular sequencing, Prognosis biomarker, Genetic cluster analysis, Guanine nucleotide binding protein (G protein) alpha 13 human

5.

Feasibility and clinical relevance of the G-CODE in older adults treated in Phase 1 Clinical Trials at Gustave Roussy

Number of pages: 15 Posted: 15 Oct 2025
Gustave Roussy - Drug Development Department (DITEP), affiliation not provided to SSRN, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, University of Paris-Saclay - Department of Hematology, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Université Paris XI Sud - Gustave Roussy Cancer Campus, Gustave Roussy - Drug Development Department (DITEP) and Gustave Roussy
Downloads 35 (1,263,436)

Abstract:

Loading...

G-CODE, geriatric assessment, phase 1 clinical trials, older adults, feasibility, Toxicity

6.

A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies

Number of pages: 21 Posted: 09 Oct 2024
Gustave Roussy - Drug Development Department (DITEP), Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, The Chinese University of Hong Kong (CUHK), Shizuoka Cancer Center, University of Cologne, University of Toronto - Princess Margaret Cancer Centre, Sarah Cannon Research Institute, affiliation not provided to SSRN, National Cancer Centre Singapore - Division of Medical Oncology, Humanitas University - Department of Biomedical Sciences, affiliation not provided to SSRN, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 22 (1,448,301)

Abstract:

Loading...

MAK683, EED, PRC2, DLBCL, ES, dose-escalation